Skip to main content
Erschienen in: Diabetologia 7/2014

01.07.2014 | Article

Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy

verfasst von: Amber A. W. A. van der Heijden, Iris Walraven, Esther van ’t Riet, Thor Aspelund, Sigrún H. Lund, Petra Elders, Bettine C. P. Polak, Annette C. Moll, Jan E. E. Keunen, Jacqueline M. Dekker, Giel Nijpels

Erschienen in: Diabetologia | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Our study aimed to validate a model to determine a personalised screening frequency for diabetic retinopathy.

Methods

A model calculating a personalised screening interval for monitoring retinopathy based on patients’ risk profile was validated using the data of 3,319 type 2 diabetic patients in the Diabetes Care System West-Friesland, the Netherlands. Two-field fundus photographs were graded according to the EURODIAB coding system. Sight-threatening retinopathy (STR) was considered to be grades 3–5. Validity of the model was assessed using calibration and discrimination measures. We compared model-based time of screening with time of STR diagnosis and calculated the differences in the number of fundus photographs using the model compared with those in annual or biennial screening.

Results

During a mean of 53 months of follow-up, 76 patients (2.3%) developed STR. Using the model, the mean screening interval was 31 months, leading to a reduced screening frequency of 61% compared with annual screening and 23% compared with biennial screening. STR incidence occurred after a mean of 26 months after the model-based time of screening in 67 patients (88.2%). In nine patients (11.8%), STR had developed before the model-based time of screening. The discriminatory ability of the model was good (C-statistic 0.83; 95% CI 0.74, 0.92). Calibration showed that the model overestimated STR risk.

Conclusions/interpretation

A large reduction in retinopathy screening was achieved using the model in this population of patients with a very low incidence of retinopathy. Considering the number of potentially missed cases of STR, there is room for improvement in the model. Use of the model for personalised screening may eventually help to reduce healthcare use and costs of diabetes care.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ding J, Wong TY (2012) Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 12:346–354PubMedCrossRef Ding J, Wong TY (2012) Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 12:346–354PubMedCrossRef
2.
Zurück zum Zitat Chalk D, Pitt M, Vaidya B, Stein K (2012) Can the retinal screening interval be safely increased to 2 years for type 2 diabetic patients without retinopathy? Diabetes Care 35:1663–1668PubMedCentralPubMedCrossRef Chalk D, Pitt M, Vaidya B, Stein K (2012) Can the retinal screening interval be safely increased to 2 years for type 2 diabetic patients without retinopathy? Diabetes Care 35:1663–1668PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Olafsdottir E, Stefansson E (2007) Biennial eye screening in patients with diabetes without retinopathy: 10-year experience. Br J Ophthalmol 91:1599–1601PubMedCentralPubMedCrossRef Olafsdottir E, Stefansson E (2007) Biennial eye screening in patients with diabetes without retinopathy: 10-year experience. Br J Ophthalmol 91:1599–1601PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Rodbard HW, Blonde L, Braithwaite SS et al (2007) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl 1):1–68PubMedCrossRef Rodbard HW, Blonde L, Braithwaite SS et al (2007) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl 1):1–68PubMedCrossRef
5.
Zurück zum Zitat Scanlon PH (2008) The English national screening programme for sight-threatening diabetic retinopathy. J Med Screen 15:1–4PubMedCrossRef Scanlon PH (2008) The English national screening programme for sight-threatening diabetic retinopathy. J Med Screen 15:1–4PubMedCrossRef
7.
Zurück zum Zitat Mehlsen J, Erlandsen M, Poulsen PL, Bek T (2011) Identification of independent risk factors for the development of diabetic retinopathy requiring treatment. Acta Ophthalmol 89:515–521PubMedCrossRef Mehlsen J, Erlandsen M, Poulsen PL, Bek T (2011) Identification of independent risk factors for the development of diabetic retinopathy requiring treatment. Acta Ophthalmol 89:515–521PubMedCrossRef
8.
Zurück zum Zitat Stratton IM, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163PubMedCrossRef Stratton IM, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163PubMedCrossRef
9.
Zurück zum Zitat Zavrelova H, Hoekstra T, Alssema M et al (2011) Progression and regression: distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the Diabetes Care System West-Friesland, the Netherlands. Diabetes Care 34:867–872PubMedCentralPubMedCrossRef Zavrelova H, Hoekstra T, Alssema M et al (2011) Progression and regression: distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the Diabetes Care System West-Friesland, the Netherlands. Diabetes Care 34:867–872PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Agardh E, Tababat-Khani P (2011) Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes Care 34:1318–1319PubMedCentralPubMedCrossRef Agardh E, Tababat-Khani P (2011) Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes Care 34:1318–1319PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR (2001) Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 18:178–184PubMedCrossRef Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR (2001) Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 18:178–184PubMedCrossRef
12.
Zurück zum Zitat Looker HC, Nyangoma SO, Cromie DT et al (2013) Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia 56:1716–1725PubMedCentralPubMedCrossRef Looker HC, Nyangoma SO, Cromie DT et al (2013) Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia 56:1716–1725PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Porta M, Maurino M, Severini S et al (2013) Clinical characteristics influence screening intervals for diabetic retinopathy. Diabetologia 56:2147–2152PubMedCrossRef Porta M, Maurino M, Severini S et al (2013) Clinical characteristics influence screening intervals for diabetic retinopathy. Diabetologia 56:2147–2152PubMedCrossRef
14.
Zurück zum Zitat Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH (2013) A simple risk stratification for time to development of sight-threatening diabetic retinopathy. Diabetes Care 36:580–585PubMedCentralPubMedCrossRef Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH (2013) A simple risk stratification for time to development of sight-threatening diabetic retinopathy. Diabetes Care 36:580–585PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Vijan S, Hofer TP, Hayward RA (2000) Cost–utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 283:889–896PubMedCrossRef Vijan S, Hofer TP, Hayward RA (2000) Cost–utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 283:889–896PubMedCrossRef
16.
Zurück zum Zitat Younis N, Broadbent DM, Vora JP, Harding SP (2003) Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 361:195–200PubMedCrossRef Younis N, Broadbent DM, Vora JP, Harding SP (2003) Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 361:195–200PubMedCrossRef
17.
Zurück zum Zitat Aspelund T, Thornorisdottir O, Olafsdottir E et al (2011) Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 54:2525–2532PubMedCrossRef Aspelund T, Thornorisdottir O, Olafsdottir E et al (2011) Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 54:2525–2532PubMedCrossRef
18.
Zurück zum Zitat Welschen LM, van Oppen P, Dekker JM, Bouter LM, Stalman WA, Nijpels G (2007) The effectiveness of adding cognitive behavioural therapy aimed at changing lifestyle to managed diabetes care for patients with type 2 diabetes: design of a randomised controlled trial. BMC Public Health 7:74PubMedCentralPubMedCrossRef Welschen LM, van Oppen P, Dekker JM, Bouter LM, Stalman WA, Nijpels G (2007) The effectiveness of adding cognitive behavioural therapy aimed at changing lifestyle to managed diabetes care for patients with type 2 diabetes: design of a randomised controlled trial. BMC Public Health 7:74PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl 1):S5–S20 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl 1):S5–S20
20.
Zurück zum Zitat Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK (1995) Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 38:437–444PubMedCrossRef Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK (1995) Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 38:437–444PubMedCrossRef
22.
Zurück zum Zitat Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387PubMedCrossRef Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387PubMedCrossRef
23.
Zurück zum Zitat Ruamviboonsuk P, Teerasuwanajak K, Tiensuwan M, Yuttitham K (2006) Interobserver agreement in the interpretation of single-field digital fundus images for diabetic retinopathy screening. Ophthalmology 113:826–832PubMedCrossRef Ruamviboonsuk P, Teerasuwanajak K, Tiensuwan M, Yuttitham K (2006) Interobserver agreement in the interpretation of single-field digital fundus images for diabetic retinopathy screening. Ophthalmology 113:826–832PubMedCrossRef
24.
Zurück zum Zitat Healy R, Sallam A, Jones V et al (2013) Agreement between photographic screening and hospital biomicroscopy grading of diabetic retinopathy and maculopathy. Eur J Ophthalmol. doi:10.5301/ejo.5000404 PubMed Healy R, Sallam A, Jones V et al (2013) Agreement between photographic screening and hospital biomicroscopy grading of diabetic retinopathy and maculopathy. Eur J Ophthalmol. doi:10.​5301/​ejo.​5000404 PubMed
Metadaten
Titel
Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy
verfasst von
Amber A. W. A. van der Heijden
Iris Walraven
Esther van ’t Riet
Thor Aspelund
Sigrún H. Lund
Petra Elders
Bettine C. P. Polak
Annette C. Moll
Jan E. E. Keunen
Jacqueline M. Dekker
Giel Nijpels
Publikationsdatum
01.07.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 7/2014
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3246-4

Weitere Artikel der Ausgabe 7/2014

Diabetologia 7/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.